Renaissance Technologies’s NRX Pharmaceuticals NRXP Stock Holding History

Renaissance Technologies’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$158K	Buy	+38,600	New	+$128K	﹤0.01%	2924
2025 Q4	–	Sell	-128,175	Closed	-$423K	–	3587
2025 Q3	$423K	Buy	+128,175	New	+$367K	﹤0.01%	2864
2024 Q2	–	Sell	-18,878	Closed	-$89K	–	3820
2024 Q1	$89K	Sell	18,878 -1,170	-6%	-$5.39K	﹤0.01%	3395
2023 Q4	$92K	Buy	20,048 +3,670	+22%	+$12.1K	﹤0.01%	3320
2023 Q3	$43K	Buy	16,378 +13,028	+389%	+$43.3K	﹤0.01%	3428
2023 Q2	$16K	Buy	3,350 +820	+32%	+$4.93K	﹤0.01%	3797
2023 Q1	$17K	Buy	2,530 +770	+44%	+$7.8K	﹤0.01%	3844
2022 Q4	$20K	Buy	1,760 +315	+22%	+$3.17K	﹤0.01%	3967
2022 Q3	$11K	Sell	1,445 -1,845	-56%	-$12.4K	﹤0.01%	3943
2022 Q2	$20K	Sell	3,290 -10,610	-76%	-$139K	﹤0.01%	4119
2022 Q1	$341K	Buy	+13,900	New	+$452K	﹤0.01%	3411

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies's NRXP Position: Q2 2026 in Review

Renaissance Technologies opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 38,600 shares worth $158K. The stake represents ﹤0.01% of the portfolio and ranks #2924 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in NRXP as recently as Q3 2025.

Renaissance Technologies first reported a position in NRXP in Q1 2022 and has held it in 11 quarters since. The position peaked at $423K in Q3 2025. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

Renaissance Technologies held 38,600 shares of NRX Pharmaceuticals worth $158K as of Q2 2026.
NRX Pharmaceuticals was a new Renaissance Technologies position in Q2 2026.
NRX Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2924 holding.
Renaissance Technologies first reported a position in NRX Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
Renaissance Technologies's NRX Pharmaceuticals position peaked at $423K in Q3 2025.
47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.